Piperazine-2,5-diones as TGF-beta inhibitors
US-11505531-B2 · Nov 22, 2022 · US
US9567305B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9567305-B2 |
| Application number | US-201414159304-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 20, 2014 |
| Priority date | Mar 24, 2011 |
| Publication date | Feb 14, 2017 |
| Grant date | Feb 14, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides oxazine compounds, method of using and method of making oxazine compounds and its pharmaceutical use.
Opening claim text (preview).
What is claimed is: 1. A compound or pharmaceutical salts thereof, wherein the compound has the formula: 2. The compound or pharmaceutical salts thereof having the formula: 3. The compound or pharmaceutical salts thereof having the formula: 4. A compound or pharmaceutical salts thereof having the formula:
Barbituric acids · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Oxygen atoms · CPC title
Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.